Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for RedHill Biopharma (RDHL) over the last 14 years, with Q2 2025 value amounting to $5.8 million.

  • RedHill Biopharma's Non-Current Assets fell 792.6% to $5.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.8 million, marking a year-over-year decrease of 792.6%. This contributed to the annual value of $6.1 million for FY2024, which is 1122.05% down from last year.
  • As of Q2 2025, RedHill Biopharma's Non-Current Assets stood at $5.8 million, which was down 792.6% from $6.1 million recorded in Q4 2024.
  • In the past 5 years, RedHill Biopharma's Non-Current Assets ranged from a high of $105.2 million in Q2 2021 and a low of $5.8 million during Q2 2025
  • In the last 5 years, RedHill Biopharma's Non-Current Assets had a median value of $8.0 million in 2023 and averaged $42.2 million.
  • As far as peak fluctuations go, RedHill Biopharma's Non-Current Assets dropped by 5.8% in 2021, and later plummeted by 9053.45% in 2023.
  • Over the past 5 years, RedHill Biopharma's Non-Current Assets (Quarter) stood at $92.0 million in 2021, then dropped by 20.72% to $73.0 million in 2022, then tumbled by 90.53% to $6.9 million in 2023, then decreased by 11.22% to $6.1 million in 2024, then dropped by 5.09% to $5.8 million in 2025.
  • Its last three reported values are $5.8 million in Q2 2025, $6.1 million for Q4 2024, and $6.3 million during Q2 2024.